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Receive date: September 21st, 2011 
In this editorial we comment on editorial policies of the Journal of Bioscience and Medicine (JBM) in relation to advancing 
the knowledge base in bioscience and medicine. These include a rapid review process, a free open publication format, 
an emphasis on “building block” research as well as novel studies, no limitation in word count, open discussion and ac-
tive distribution of papers to a relevant audience of scientific colleagues; and most importantly, publication of both posi-
tive and negative results papers.   We argue that given the role probability in science and self-correcting nature of scien-
tific inquiry, the scientific community must have access to the full range of evidence for and against specific hypotheses 
and associations; from this perspective, negative results in papers meeting quality standards should be treated no differ-
ently than positive results. Moreover, we suggest specific guidelines for presenting negative results, reviewing negative 
results, and most importantly, deciding when to submit negative results to peer review. Among these guidelines is the 
GRADE (Grades of Recommendation, Assessment, Development, and Evaluation) approach to evaluating the quality of 
the research and presentation of data in formats reasonable for interpretation of negative and positive finding. More gen-
erally we argue that one of the most significant reasons that negative results are not published is the reluctance of inves-
tigators to publish negative results. We suggest that positive decisions to submit negative results data may be more likely 
for journals such as JBM that publish both positive or negative results in a balanced fashion rather than focusing on ei-
ther negative and positive results papers.  
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pectoris, nutrition, and depressed mood. His current interest is in relating pulse wave velocity (a measure of 
arterial stiffness) to cognition and relations between mild renal dysfunction and cognition. His studies, and 
those of my his, are done in a life-span developmental context and involve cross-sectional differences and 
longitudinal designs. Much of the data for his work, and the work of his students, comes from their own 
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Study. His teaching interests are experimental design, biostatistics and epidemiological approaches to the 
study of cognitive functioning. 
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  The Journal of Bioscience and Medicine (JBM) will publish its inaugural issue in winter of 
2011. There are a number of editorial policies that make this journal an attractive publica-
tion vehicle for researchers in the biological, epidemiological, bio-behavioral, and medical 
sciences. We review each of these in the sections that follow and comment on their scien-
tific merits. Finally, we provide a detailed commentary on the issues involved in reviewing 
null results papers and in making a decision to publish null results. 
Quick Review Process.  
  The goal is a manuscript turnaround time of four weeks from submission. This goal is 
within the time envelope developed by the major journals in bioscience and medicine. The 
“proof of the pudding is in the tasting” and thus the editors’ success in achieving this goal 
will be very important to the success of the journal. A number of documents on the ethics 
and considerations in review of scientific papers are available and useful, and include is-
sues such as confidentiality, conflict of interest, objectivity, expertise, and timeliness [1]. 
No Publication Costs. 
  This is a very important element in the success of the journal and balanced science at a 
time when funding for research is decreasing and grant funding for publication fees is ex-
hibiting a parallel decrease. It is important that science not be represented solely by those 
investigators who have resources to pay for publication fees.  Moreover, there are few 
researchers, at least in the older generation of scientists, who do not recall the stigma of 
the “pay journal.” Clearly that stigma may not be deserved, as even high impact journals 
now charge for extra pages using a very conservative figure for standard journal length. 
  There are experimental data indicating that articles made free-to-the reader via the open 
access journals were cited more often [2, 3]. It is likely that this trend will continue and in-
crease demand for open access journals for which there is no publication charge.  
Novelty is Not a Requirement for an Acceptable Paper. 
  Novelty is clearly the hallmark of exciting new science, but it requires subjective judg-
ment on the part of the reviewer and precludes publication of failures to replicate or appli-
cations of previous findings to new problems. After all, buildings are supported by many 
more bricks than cornerstones, and there is growing recognition of the important role of 
negative results in clinical trial reporting [4] and negative results in the general research 
literature [5].  
No Limitation on Length. 
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  This is an attractive feature at a time when many print publication journals are forced to 
limit word count, and utilize supplements and references to previous papers with the meth-
odological details. While these are reasonable solutions, they force readers with significant 
interest in a paper to make the extra effort to track previous papers and access supple-
mentary materials. Moreover, there are few authors who have not been frustrated by peer 
review advice as to reduce the word count while simultaneously to add information on re-
sults, methods, and elaboration of discussion points. Obviously the researcher who cannot 
practice reasonable constraint will produce a product that will not be well accepted by re-
viewers or readers, but many authors are likely to welcome the opportunity to match the 
length of their papers to the scope and the detail required to communicate their research 
accurately and effectively. 
Open Discussion. 
  This is a particularly attractive feature of the journal, i.e., an option that allows reviewers 
to publish their comments in the journal. Here again good ethics and constraint are im-
portant as reviewers must refrain from “pulling their punches” during the review process to 
save material for commentary.  Allowing rebuttal by authors serves to prevent this use of 
the review commentary and initiates a very exciting flow of scientific discourse which was 
alive and well in all sciences at the turn of the century, but has faded in parallel to con-
straints on length and increase in publication cost for print journals.  
Distribution of Papers by JBM.  
  The journal will actively distribute published articles to potentially interested readers. 
Most scientists realize that public relations considerations are part of the scientific pro-
cess, but few have the time to circulate papers to all potentially interested colleagues. 
Most will welcome this feature and, as scientists, we welcome receipt of papers relevant to 
our work.  
Negative Results are Acceptable for Publication. 
  This is one of the most important features of science and thus one of the major positive 
features of JBM. However, it is important to have knowledge of the important technical 
issues with regard to the publication of null findings. Thus, we will expand our comments 
on the merits of this negative results publication policy by providing a review of the im-
portant reasons why publication of negative results is so critical to good sciences. 
Why Are Negative Results Important?  
 Merrill F. Elias et al.| Inaugural editorial 
 
 
Editorial 
Open Discussion. 
Negative Results. 
No Limitation on 
Length. 
 www.jbscience.org 
DOI: 10.5780/jbm2011.1 | Page 4 
 Merrill F. Elias et al.| Inaugural editorial 
 
 
Editorial 
  As most all of us have been taught in methods courses: “Most broadly, findings from 
good research are the subject matter of science, regardless of whether the results support 
particular hypotheses” [6, p. 742]. In a short essay on this topic, Probst [6], citing Dickersin 
[7], points out that the systematic failure of journals to publish articles with null results 
leads to a disproportionate representation in the literature on positive results (most often 
defined as statistically significant results). She [6] makes the important point that statistical 
methods for meta-analyses have been developed to compensate for the under-
representation of null findings [8] because this problem is so widely recognized. In his 
book “Hyping Health Risks,” epidemiologist G.C. Kabat [9] makes excellent points about 
the roles of societal beliefs and preferences and biases internal and external to medicine, 
including political agendas, which encourage the selective reporting of negative and posi-
tive results. 
  Giraud-Carrier and Dunham [10] make the important point that failure experiences need 
to be accessible to fellow researchers who may otherwise spend needless time on a pro-
ject or a hypothesis, or who could build from those results with a new methodological ap-
proach. Probst [6] argues that ethical considerations in human research require that the 
research findings, negative or positive, be communicated and that this is most important in 
clinical trials when an intervention is not successful. In the context of educational policy 
this author [6] points out that an apparently sound but ineffective intervention, if not contra-
dicted via publication of negative results, might be employed for generations of students. 
  Magnitude of effect is an important consideration even when the null hypothesis is reject-
ed. Despite clinically significant results, investigators are obligated to comment on the clin-
ical and/or epidemiological significance of the findings and to be very clear where effect 
sizes or practical importance of the results are minimal. The confusion between statistical 
significance and significance in terms of effect size continues in the literature despite argu-
ments against strict adherence to p-value rules as indicators of importance of a research 
finding [11].  
  Journal policy, reviewer and editor bias, indirect pressures related to funding, and self-
censorship are some reasons offered for this trend to not publish null results [6], although 
a recent report from the CONSORT group [12] suggests that rejection by a journal was 
much less commonly mentioned by researchers as a reason for failing to publish negative 
findings. Thus, selective submission may be as important in creating bias toward positive 
findings as selective recommendations through peer review or selective acceptance by 
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editors. As a solution to bias toward positive results the Journal of Cerebral Blood Flow 
and Metabolism has introduced a negative result section [13], and there are journals that 
are dedicated to negative results, including the Journal of Negative Results in Biomedicine 
[14], the Journal of Negative Results [15], and the Journal of Interesting Negative Results 
[16]. While this is a very positive trend in publication of scientific information, investigators 
may be much more willing to submit negative result findings to a journal that accepts pa-
pers of both varieties as the imbalanced presentation of the negative results journal may 
suggest that negative results papers are of intrinsically less value and not worthy of main-
stream publication.  In this context we note that the Journal of Interesting Negative Re-
sults, although devoted to important negative results papers, was started in April 2008 and 
appears to have published only 1 paper [16]. The Journal of Negative Results in Biomedi-
cine has a better record as it has published approximately 96 articles, including commen-
taries on articles, between 2002 and 2011 [14]. 
  It is difficult to take issue with the fact that negative results are important and it is im-
portant that JBM is accepting papers with negative results. Just as for positive results, one 
must define which negative results papers are acceptable and worthy of publication.  In 
the sections below, we argue that the decision should be based on the quality of the meth-
ods, not the result obtained.  
Evaluating a Negative Result Paper. 
  There has been a long debate on null hypothesis significance testing (NHST) and effect 
size testing (EST) for generating a cumulative knowledge base in the behavioral sciences, 
and it has now run its course several times. Issues include the importance of considering 
both parameter estimates and confidence intervals [17], issues necessary for training 
scholars [18] and the importance of model building and model testing [19] and effect size 
testing [20]. What is clear in this process is that evidence differs in the quality of both infer-
ence and recommendations. 
  Journals which explicitly encourage or permit submission of negative findings potentially 
eliminate or reduce the potential bias of selective submission. Some journals further distin-
guish between studies which present negative results and those which are methodologi-
cally sound but under-powered (e.g., pilot studies designed to bracket effect sizes rather 
than to test group difference treatment effects). Hurdles that remain, then, pertain to evalu-
ating the scientific rigor of a manuscript based upon the quality and integrity of a particular 
study. In recent years, epidemiologists have worked to develop consensus on how to eval-
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uate research studies. 
  One large-scale example of this is the GRADE (Grades of Recommendation, Assess-
ment, Development, and Evaluation) approach [21-25]. An envisioned 20-part article se-
ries in the Journal of Clinical Epidemiology [26], the first nine installments of which are al-
ready in print or in press, considers guidance for researchers to evaluate the quality of 
evidence and strength of recommendations of research in health care. Although the over-
all framework is oriented toward research synthesis in the form of systematic reviews, 
many of the guidelines it provides are also useful for evaluating the quality of evidence 
within a specific study, and offer an explicit and structured approach to summarizing evi-
dence. Reviewers of negative findings should consider the confidence that effect esti-
mates are correct alongside confidence that effect estimates are adequate to support clini-
cal decisions and recommendations. 
  Central to consideration of studies presenting negative findings is sensitivity to the preci-
sion of estimates, such as evidenced by 95% confidence intervals. Depending on goals 
and perspective, reviewers may wish to consider the accuracy in parameter estimation 
(AIPE) [27] and/or optimal information size (OIS) [28] associated with a particular study. 
Reviewers should be sensitive not just to evidence for or against specific hypotheses, but 
rather what new information is gained about the likely range within which a specific effect 
is likely to reside. In testing statistical hypotheses, what is obtained is the probability of the 
data given that the null hypothesis is true. What researchers really want to know, however, 
is the probability that the null hypothesis is true given the data. This latter quantity, the in-
verse probability, is only obtainable through Bayes’ theorem [29, 30], a set of statistical 
rules requiring assumptions about the prior probability or distribution of probabilities. How-
ever, one need not master Bayes’ theorem in order to make common-sense decisions 
about the quality of the methods in a negative results study or to present the data in the 
best possible way for clear interpretation of their importance.  
Summary 
  Many researchers contend that a study is never completed until it has been published, 
and this is a valid argument. It is likely that an investigator or investigative team may be 
the most important single factor behind the lack of publication of null or negative findings, 
rather than journal editors or reviewers. We argue that research should be evaluated on its 
intrinsic merits, i.e., the quality of the methods, procedures, and analyses used, rather 
than on the nature of its results. 
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  The use of probability in science and the self-correcting nature of scientific inquiry de-
pends on a research community that has access to the full range of evidence for and 
against specific hypotheses and associations; from this perspective negative results 
should be treated no differently than positive results [31]. In evaluating research, particu-
larly with negative or null findings, approaches beyond null hypothesis significance testing 
are essential. Confidence intervals provide very important information about the likely 
range within which an effect or difference is likely to be found, and there are many exam-
ples of effective presentation of data using this vehicle [23, 32, 33]. From this perspective, 
studies with larger sample sizes more successfully bracket these effects than studies with 
smaller sample sizes. In many contexts, an emphasis on accuracy in parameter estimation 
can be a useful extension to confidence intervals. 
  Many different frameworks can be applied to evaluate the soundness and rigor of scien-
tific research, regardless of their findings. In this paper, we provide links to the emerging 
GRADE framework as one example. The GRADE framework is broad and systematic in its 
scope, and written with a clinical research audience in mind. Within the GRADE frame-
work, imprecision is considered as just one of several components in evaluating the quali-
ty of the evidence a study provides. As more journals, editors, and reviewers provide posi-
tive experiences for researchers interested in publishing null or negative findings, perhaps 
this barrier to generating a more cumulative scientific knowledge base will diminish. One 
necessary first step in this important objective is a journal policy that encourages submis-
sion of both positive and negative results studies. Quality review with rapid turnaround, no 
publication charges, no limitations on length, and distribution of papers to a potential inter-
esting audience are additional features that will make the Journal of Bioscience and Medi-
cine an important vehicle for achieving this goal.  
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